ECM represents a platform technology that addresses unmet clinical needs in a number of markets that either have no effective therapy or only marginally effective therapy. Extensive bench-top laboratory work, preclinical animal studies, human clinical experience with alternative forms of ECM-based surgical mesh materials, scientific publications, and an extensive patent portfolio have positioned the company to develop products to address these needs.

Pipeline

Discovery Pre-Clinical Data Phase I Phase II FDA Approval Market Entry
Esophageal Disease Products
EsophaGard™
EsophaLift™
EsophaGel™
CNS Applications
Stroke
Glioblastoma
Traumatic Brain Injury
Ocular Applications
Retinal Disease
Optic Nerve Trauma
Corneal Ulcers
Musculoskeletal Applications
Ventral Hernia
Tendon Repair
Volumetric Muscle Loss
Arthritis
Topical Wound
Diabetic Ulcers
Venous Statis Ulcers
Decubiti (Bed Sores)
Burns

EsophaGel™

For Esophageal Repair

An extracellular matrix hydrogel that can prevent stricture following mucosal resection in the esophagus

Naturally occurring, biologic sheet materials composed of extracellular matrix (ECM) have been successfully used for almost 20 years as surgical meshes and topical powders.

Aims to reduce the number of dilation events and frequency of patient follow up visits due to stricture complications after endoscopic eradication therapy by promoting constructive epithelial remodeling via noninvasive delivery, allowing surgeons to more aggressively remove lesions in the upper GI tract.

Market for Esophageal Applications

Esophageal cancer affects approximately 17,000 new patients each year in the U.S. alone. Four out of five patients diagnosed with esophageal cancer die within 5 years in spite of current best current treatment options.

3-4x more common among men than women

50% more common in African Americans than Caucasians

5 year survival is only 20%